Valuation : Orion Oyj

Market Cap 11.23B 13.04B 10.56B 9.65B 18.04B 1,232B 18.1B 125B 48.36B 631B 48.95B 47.88B 2,038B P/E 2026 *
19.8x
P/E 2027 * 16.8x
Enterprise Value 11.14B 12.94B 10.48B 9.57B 17.9B 1,222B 17.95B 124B 47.98B 626B 48.55B 47.49B 2,021B EV / Sales 2026 *
5.31x
EV / Sales 2027 * 4.59x
Free-Float
90.5%
Yield 2026 *
2.44%
Yield 2027 * 2.72%
1 day+4.81%
6 months+4.81%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37.44
Extreme 37.44
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 31/10/2022
Director of Finance/CFO 50 30/04/2024
Chief Operating Officer 46 31/12/2021
Director TitleAgeSince
Director/Board Member 63 21/03/2017
Director/Board Member 65 21/03/2017
Director/Board Member 66 05/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 13.05B
-0.88%-2.15%+58.05%+105.91% 1,024B
-1.15%+2.68%+54.25%+71.29% 663B
-1.44%+0.38%+20.65%+75.54% 453B
+0.14%-0.47%+30.20%+40.61% 352B
-1.33%+4.72%+24.62%+47.60% 304B
-1.15%+0.30%-0.69%+11.83% 252B
-1.55%+1.11%+54.15%+72.13% 236B
-0.88%+1.15%-14.60%-54.84% 206B
-0.15%+3.65%+31.24%+100.90% 187B
Average -0.36%+1.09%+28.65%+52.33% 408.71B
Weighted average by Cap. -0.94%+0.55%+37.63%+67.00%

Financials

2026 *2027 *
Net sales 2.1B 2.44B 1.97B 1.8B 3.37B 230B 3.38B 23.31B 9.03B 118B 9.14B 8.94B 381B 2.37B 2.76B 2.23B 2.04B 3.81B 260B 3.82B 26.37B 10.22B 133B 10.34B 10.12B 431B
Net income 566M 657M 532M 486M 909M 62.08B 912M 6.29B 2.44B 31.81B 2.47B 2.41B 103B 668M 775M 628M 574M 1.07B 73.27B 1.08B 7.42B 2.88B 37.55B 2.91B 2.85B 121B
Net Debt -89.76M -104M -84.43M -77.1M -144M -9.85B -145M -997M -387M -5.05B -391M -383M -16.28B -333M -387M -313M -286M -535M -36.53B -536M -3.7B -1.43B -18.72B -1.45B -1.42B -60.4B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
79.80EUR
Average target price
76.67EUR
Spread / Average Target
-3.93%

Quarterly revenue - Rate of surprise